Company intelligence / Profile preview
Chemomab Therapeutics
Tel Aviv, Tel Aviv, Israelchemomab.com ↗
- Ownership
- Public · CMMB
- Employees
- ~20
- Development stage
- Phase 2
01
Overview
Chemomab’s lead asset nebokitug (CM‑101) has demonstrated positive results in multiple Phase 2 trials, particularly in primary sclerosing cholangitis. The SPRING trial met its primary endpoint with a favorable safety profile and showed improvements across fibrotic, inflammatory, and cholestatic biomarkers—suggesting potential disease-modifying effects. The FDA has agreed to a streamlined single pivotal Phase 3 trial design without liver biopsies or confirmatory studies.
- Therapeutic areas
- Metabolic DisordersGastroenterologyPulmonologyRheumatology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Ongoing discussions with potential strategic partners; no major public pharma partnerships disclosed as of latest updates
Beyond the preview
Go deeper on Chemomab Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chemomab Therapeutics.